Exelixis, Inc. (EXEL): A Bull Case Theory [Yahoo! Finance]
Exelixis, Inc. (EXEL)
Last exelixis, inc. earnings: 2/25 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.exelixis.com/phoenix.zhtml?c=120923&p=irol-mediaresources
Company Research
Source: Yahoo! Finance
Exelixis, Inc.'s share was trading at $44.08 as of January 13th. EXEL's trailing and forward P/E were 18.52 and 15.24 respectively according to Yahoo Finance. Photo by National Cancer Institute on Unsplash Exelixis (EXEL) is a biopharmaceutical company focused on the discovery, development, and commercialization of oncology therapies, with a clear emphasis on durable growth and capital efficiency. The company's core value driver is Cabometyx, a flagship cancer drug approved across multiple kidney and liver cancer indications, which continues to generate strong, recurring cash flows while funding a deep and expanding pipeline of experimental oncology treatments. This combination of a mature, high margin commercial product and a broad pipeline positions Exelixis as an aggressive quality growth name within the healthcare and biotech sector, rather than a binary, early-stage biotech story. Financially, Exelixis exhibits highly resilient and anti fragile characteristics that set it
Show less
Read more
Impact Snapshot
Event Time:
EXEL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EXEL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EXEL alerts
High impacting Exelixis, Inc. news events
Weekly update
A roundup of the hottest topics
EXEL
News
- Exelixis (NASDAQ:EXEL) was given a new $51.00 price target on by analysts at Truist Financial Corporation.MarketBeat
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026 [Yahoo! Finance]Yahoo! Finance
- Exelixis Announces Preliminary Fiscal Year 2025 Financial Results, Provides 2026 Financial Guidance and Outlines Key Priorities and Milestones for 2026Business Wire
- How Natera ctDNA Partnership Around STELLAR-316 At Exelixis (EXEL) Has Changed Its Investment Story [Yahoo! Finance]Yahoo! Finance
- Assessing Exelixis (EXEL) Valuation After Zanzalintinib Phase 3 Success And STELLAR-316 Trial Plans [Yahoo! Finance]Yahoo! Finance
EXEL
Earnings
- 11/4/25 - Beat
EXEL
Sec Filings
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- 1/16/26 - Form 4
- EXEL's page on the SEC website